Cabaletta Bio Inc. Unveils Corporate Presentation on Pioneering Cellular Therapies for Autoimmune Diseases
I'm PortAI, I can summarize articles.
Cabaletta Bio Inc. has unveiled a corporate presentation detailing its plans for the development and submission of a biologics license application (BLA) for resecabtagene autoleucel (rese-cel) in 2027, following FDA alignment. The company aims to accelerate enrollment across 62 clinical sites, initially targeting myositis, with future expansions to lupus and systemic sclerosis. The presentation emphasizes an innovative clinical strategy and highlights FDA Fast Track and RMAT designations. New data will be presented at the EULAR 2025 congress.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments